CD52 and Burkitt lymphoma: The results of additional immunohistochemical studies (BCL2, MYC, Ki67) showed no impact on CD52 expression status, and tumor morphology (blastoid vs. DLBCL vs. DLBCL/BL) was similarly non-predictive.